Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS. We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling. This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS. Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice. Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression. They highlight the importance of understanding pathway signaling in clinical practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.

Pubmed ID: 20141835


  • Heidorn SJ
  • Milagre C
  • Whittaker S
  • Nourry A
  • Niculescu-Duvas I
  • Dhomen N
  • Hussain J
  • Reis-Filho JS
  • Springer CJ
  • Pritchard C
  • Marais R



Publication Data

January 22, 2010

Associated Grants

  • Agency: Wellcome Trust, Id: 080333/Z/06/Z
  • Agency: Cancer Research UK, Id: 10433
  • Agency: Cancer Research UK, Id: 10437
  • Agency: Cancer Research UK, Id: 13083
  • Agency: Cancer Research UK, Id: C107/A10433

Mesh Terms

  • Animals
  • Antineoplastic Agents
  • Cell Line, Tumor
  • Humans
  • Melanoma
  • Mice
  • Mice, Transgenic
  • Proto-Oncogene Proteins B-raf
  • Proto-Oncogene Proteins c-raf
  • ras Proteins